TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 2 months of age (54-75 days of age) on date of first vaccination~* Healthy assessed from medical history and physical examination~* Parent(s)/guardian(s) have been properly informed about the trial and signed informed consent form~* Parent(s)/guardian(s)granted access to the infant's trial related medical records~* Parent(s)/guardian(s)are likely to comply with trial procedures~Exclusion Criteria:~* Vaccinated with any polio vaccine other than the trial vaccines, prior to inclusion or planned during the trial~* OPV vaccination or known exposure to poliovirus (wild or vaccine-derived) in household (living together) within 3 months prior to inclusion or planned during the trial~* Low birth weight (\< 2,500 g)~* Known or suspected immunodeficiency (e.g. leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criteria~* Severe uncontrolled chronic (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine) disease~* Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)~* Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~* Treatment with a product which is likely to modify the immune response (e.g. systemic corticosteroids, blood products and immunoglobulins) prior to inclusion or planned during the trial period~* Participating in another clinical trial~* Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 54 Days
- Maximum Age: 75 Days
- Healthy Volunteers: t

Study Arms:
- IPV-Al SSI (Type: EXPERIMENTAL): IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
- IPV SSI (Type: ACTIVE_COMPARATOR): IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil and Glycemic Response in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries)~* Surgery with use of cardiopulmonary bypass~* Patients over 18 years of age~* Both female and male genders~* All races~Exclusion Criteria:~* Minimally invasive heart surgery through thoracotomy approach~* Patients receiving regional analgesia such as intrathecal morphine~* Patients undergoing procedures under deep hypothermic circulatory arrest~* Patients with active infections such as acute infective endocarditis~* Emergency surgery~* Patients undergoing transplantations and ventricular assist device insertion~* Patients on any mechanical circulatory support preoperatively~* Patient's refusal~* Allergy to remifentanil~* Positive pregnancy test~* Morbid obesity~* End stage liver and kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remifentanil group (Type: EXPERIMENTAL): Half of subjects enrolled will be randomized to the remifentanil group
- Fentanyl group (Type: ACTIVE_COMPARATOR): Half of subjects enrolled will be randomized to the fentanyl group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Biopsy-proven, previously untreated, squamous cell carcinoma of the glottic and supraglottic larynx that would normally require total laryngectomy Stage III/IV disease (excluding T1 and M1) Endoscopic tumor staging required within 4 weeks of entry Tumors must be considered resectable and potentially curable with conventional surgery and radiotherapy T4 disease limited to: Up to 1 cm invasion of the base of tongue Questionable cartilage invasion on CT (clinically T3) Measurable disease required No synchronous primary tumors No subglottic tumors~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100% Hematopoietic: (obtained within 3 weeks of entry) WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal: (obtained within 2 weeks of entry) Creatinine clearance at least 50 mL/min (measured or calculated) Serum calcium normal Cardiovascular: Status adequate to tolerate all protocol therapy Pulmonary: Status adequate to tolerate all protocol therapy Other: Nutritional status adequate to tolerate all protocol therapy Mental status adequate to follow instructions and keep appointments No second malignancy except nonmelanomatous skin cancer (Patients who have been disease-free for at least 3 years following treatment for a prior cancer may be eligible at the discretion of the protocol chairman) Negative pregnancy test required of fertile women Effective contraception required of fertile women~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior therapy Chemotherapy: No prior therapy Endocrine therapy: No prior therapy Radiotherapy: No prior radiotherapy to the head and neck Surgery: No prior therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of CF~2. Patients aged 18 - 65 years of age who can give informed consent~3. FEV1 \>25% or \<75% predicted (in keeping with Cayston® license)~4. Admitted to the Liverpool Heart \& Chest Hospital with an exacerbation of CF pulmonary disease~5. Presence of PA in lower respiratory tract cultures in the 6 months prior~Exclusion Criteria:~1. Documented allergy to beta-lactam antibiotics or IV Colistin~2. Growth of Burkholderia Cepacia Complex (BCC) within 2 years~3. Pregnancy~4. Previous organ transplant~5. Receiving other clinical trial medication~6. Already prescribed regular Cayston®

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AZLI then Standard Care (Type: EXPERIMENTAL): Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
- Standard Care then AZLI (Type: ACTIVE_COMPARATOR): Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women 55-80 years of age;~* post-menopausal for \>=5 years;~* ambulatory.~Exclusion Criteria:~* malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed);~* breast cancer within the previous 20 years;~* allergy to bisphosphonates;~* previous treatment with an intravenous bisphosphonate at any time;~* previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within the last year, or \>3 months of treatment within the last 2 years.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): oral placebo daily and IV ibandronate 2 mg q 2 mo
- 2 (Type: EXPERIMENTAL): oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
- 3 (Type: EXPERIMENTAL): oral placebo daily and IV ibandronate 3 mg q 3 mo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition);~* BMI in the obesity (BMI \>30 and \<50) or non-obesity (BMI \>21.5 and \<29.9) range;~* Available for the duration of the treatment and follow-up (15 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials.~Exclusion Criteria:~* Currently taking opioid pain medications or drugs; or positive drug screen for opiates~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa or bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NB Medication (Type: EXPERIMENTAL): Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be inactive and taken daily in pill form.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patient with a dysfunctional or thrombosed forearm or upper arm prosthetic vascular access graft.~* The target lesion starts less than or equal to 30 mm from the venous anastomosis.~* The target lesion has \> 50% stenosis as measured per protocol.~* The patient has a maximum of one secondary stenosis.~Exclusion Criteria:~* The age of the hemodialysis access graft is less than or equal to 30 days old from the date of the study procedure.~* The patient has undergone an intervention (surgical or percutaneous) of the vascular access circuit less than or equal to 30 days from the date of the study procedure.~* The secondary lesion is an occlusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIABAHN Treatment Group (Type: EXPERIMENTAL): Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
- PTA Treatment Group (Type: ACTIVE_COMPARATOR): Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Ropivacaine Irrigation in Bariatric Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) \>40 Kg/m2~* BMI \> 35 Kg/m2 with the presence of comorbidities associated to obesity.~Exclusion Criteria:~* patients undergoing other bariatric techniques or revisional surgery~* allergy to local anesthetics~* severe underlying cardiovascular diseases~* chronic renal failure~* hepatic dysfunction~* previous foregut surgery~* patients with any contraindication for bariatric surgery.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine irrigation (Type: EXPERIMENTAL): Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
- Normal saline irrigation (Type: PLACEBO_COMPARATOR): Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion criteria:~* Elevated plasma Lp(a) ≥ 150nmol/L.~* All subjects must agree to adhere to appropriate contraception requirements.~* Subjects must provide written informed consent and be able to comply with all study requirements.~* Body mass index of ≥ 18 kg/m2 and ≤ 45 kg/m2.~* For the MD part: confirmed history of stable atherosclerortic cardiovascular disease.~Exclusion criteria:~* Single Ascending Dose only: any history of clinically overt cardiovascular disease, defined as acute coronary syndromes, myocardial infarction, stable angina, coronary or other revascularization, ischemic stroke or transient ischemic attack and atherosclerotic peripheral arterial disease.~* Multiple Dose only: recent history of acute cardiovascular disease events within 6 months of screening (including, but not limited to, acute myocardial infarction, unstable angina, acute stroke and acute limb ischemia).~* Moderate or severe hepatic cirrhosis with Child-Pugh grade B or C, or other current or previous liver disease.~* Active serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or severe depression requiring current pharmacological intervention.~* Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrolment in the study or could interfere with the subject's participation in, or completion of the study.~* Subjects with previous or current use of medication or therapies significantly affecting Lp(a) level or hormone replacement therapy, unless on a stable dose for ≥ 8 weeks prior to screening~* History or clinical evidence of alcohol or illegal drug misuse within the 6 months before screening.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc, or intolerance to s.c. injections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- 100 mg (Type: EXPERIMENTAL): None
- 300 mg (Type: EXPERIMENTAL): None
- 600 mg (Type: EXPERIMENTAL): None
- 900 mg (Type: EXPERIMENTAL): None
- 100 mg multi dose (Type: EXPERIMENTAL): None
- 200 mg multi dose (Type: EXPERIMENTAL): None
- 300 mg multi dose (Type: EXPERIMENTAL): None
- 600 mg multi dose (Type: EXPERIMENTAL): None
- Placebo multi dose (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65 or older~* Mini-Mental State Examination (MMSE) score 23 or greater~* Vision scored greater than 20/50~* Minimal dependence in hygiene, bathing, and dressing~Exclusion Criteria:~* Significant decline in cognitive skills, physical abilities, or functional independence~* Inability to complete study activities as evidenced by MMSE and vision scores lower than Inclusion Criteria requirement~* Diagnosis of Alzheimer's disease~* Stroke in previous 12 months~* Cancer with limited life expectance~* Current chemotherapy or radiation treatment~* Communication problems~* Planned move from study area~* Scheduling conflicts that would preclude participation in study activities~* Prior involvement in similar cognitive training studies

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Memory Training (Type: ACTIVE_COMPARATOR): Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
- Reasoning Training (Type: ACTIVE_COMPARATOR): Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
- Speed of Processing Training (Type: ACTIVE_COMPARATOR): Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
- Control (Type: PLACEBO_COMPARATOR): This group did not complete any cognitive training interventions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* On a stable daily dose of atorvastatin, rosuvastatin or simvastatin.~* Lipids meet the following criteria at screening and prior to dosing: Fasting LDL-C greater than 100 mg/dL and fasting TG less than 400 mg/dL~Exclusion Criteria:~* History of a cardiovascular or cerebrovascular event or procedure during the past year.~* Poorly controlled type 1 or type 2 diabetes mellitus.~* Poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None
- Treatment D (Type: EXPERIMENTAL): None
- Treatment E (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Peripheral Prism Glasses for Hemianopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age.~* Sighted in both eyes, with monocular visual acuity (best corrected vision), of at least 20/50 in each eye.~* Complete homonymous hemianopia of more than 3 months duration~* Refractive error within the -5 dioptre to +5 dioptre range~* No significant cognitive impairment~* No history of wearing the Peli system of peripheral prisms for hemianopic field expansion (patients who have worn another type of prismatic correction for hemianopia such as yoked prisms or the Gottlieb VAS system can participate in the study)~* No physical or mental disabilities, including cognitive dysfunction, balance problems or other deficits that could impair ability to walk or use the peripheral prism spectacles.~* Able to walk (using a cane or walker is OK) or control the movements of their own wheelchair.~* In sufficiently good health to attend four in-office visits.~Exclusion Criteria:~* Diagnosis of dementia~* Diagnosis of visual neglect~* History of seizures in the last 6 months~* Incomplete hemianopia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Real prism glasses first, then sham (Type: EXPERIMENTAL): Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
- Sham prism glasses first, then real (Type: EXPERIMENTAL): Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete